Skip to main content

Table 3 Relation of age at menarche to tumor-defined characteristics of breast cancer

From: The influence of menstrual risk factors on tumor characteristics and survival in postmenopausal breast cancer

 

Age at menarche, years

 

Odds ratio (95% confidence interval)a, b

Tumor characteristic

≤11

> 11 and ≤13

> 13 and ≤14

Tumor size

   

   1–10 mm

   

   11–20 mm

1.00 (0.65–1.53)

0.96 (0.74–1.25)

1.01 (0.76–1.33)

   ≥21 mm

1.05 (0.64–1.72)

1.43 (1.06–1.92)

1.32 (0.96–1.81)

Grade

   

   Low

   

   Medium

2.05 (1.00–4.19)

1.47 (1.00–2.15)

1.74 (1.15–2.62)

   High

2.04 (1.01–4.16)

1.55 (1.06–2.26)

1.45 (1.00–2.19)

ER status

   

   Positive

   

   Negative

1.33 (0.82–2.16)

0.94 (0.68–1.29)

1.15 (0.83–1.61)

PR status

   

   Positive

   

   Negative

0.86 (0.54–1.36)

0.99 (0.75–1.30)

1.24 (0.93–1.66)

Lymph node involvement

   

   Absent

   

   Present

1.49 (1.02–2.19)

1.29 (1.02–1.65)

1.22 (0.95–1.58)

Histology

   

   Ductal

   

   Lobular

1.17 (0.68–2.01)

1.08 (0.76–1.52)

0.99 (0.68–1.43)

   All other

0.68 (0.39–1.18)

1.09 (0.81–1.46)

0.92 (0.66–1.26)

  1. aReference group: age at menarche of more than 14 years, with the category of best prognosis within each tumor characteristic. bOdds ratio estimates adjusted for body mass index at 18 years of age, age at first birth, age at diagnosis, and ever use and type of menopausal hormone therapy (never users, exclusive estrogen therapy, and combined estrogen-progestin therapy). ER, estrogen receptor; PR, progesterone receptor.